Rapid Dose Therapeutics Past Earnings Performance
Past criteria checks 0/6
Rapid Dose Therapeutics has been growing earnings at an average annual rate of 16.6%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 20.2% per year.
Key information
16.6%
Earnings growth rate
27.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 20.2% |
| Return on equity | n/a |
| Net Margin | -400.1% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Rapid Dose Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 1 | -5 | 4 | 0 |
| 31 May 24 | 1 | -5 | 3 | 0 |
| 29 Feb 24 | 1 | -4 | 3 | 0 |
| 30 Nov 23 | 1 | -4 | 3 | 0 |
| 31 Aug 23 | 1 | -3 | 2 | 0 |
| 31 May 23 | 1 | -3 | 3 | 0 |
| 28 Feb 23 | 1 | -4 | 3 | 0 |
| 30 Nov 22 | 1 | -9 | 5 | 0 |
| 31 Aug 22 | 1 | -10 | 5 | 0 |
| 31 May 22 | 1 | -9 | 5 | 0 |
| 28 Feb 22 | 2 | -8 | 5 | 0 |
| 30 Nov 21 | 2 | -2 | 3 | 0 |
| 31 Aug 21 | 2 | -2 | 2 | 0 |
| 31 May 21 | 2 | -1 | 2 | 0 |
| 28 Feb 21 | 1 | -2 | 2 | 0 |
| 30 Nov 20 | 0 | -2 | 2 | 0 |
| 31 Aug 20 | -1 | -5 | 3 | 0 |
| 31 May 20 | 0 | -5 | 4 | 0 |
| 29 Feb 20 | 0 | -8 | 7 | 0 |
| 30 Nov 19 | 0 | -17 | 7 | 0 |
| 31 Aug 19 | 1 | -15 | 7 | 0 |
| 31 May 19 | 0 | -14 | 6 | 0 |
| 28 Feb 19 | 0 | -11 | 3 | 0 |
| 30 Nov 18 | 0 | -3 | 2 | 0 |
| 31 Aug 18 | 0 | -2 | 2 | 0 |
Quality Earnings: DOSE is currently unprofitable.
Growing Profit Margin: DOSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DOSE is unprofitable, but has reduced losses over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare DOSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DOSE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: DOSE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.